Craif Launches My Signal with Japan's First Municipal Public Subsidy Introduction
NQ Score
42/100
N1 Content Completeness
4
AI Summary (NQ-processed)
Craif Inc., in collaboration with Misato Town, Shimane Prefecture, will launch "My Signal," a urine-based cancer screening test with municipal public subsidy, starting April 2026. This is Japan's first such initiative, leveraging bio-AI technology to enable early cancer detection in regions facing medical access challenges, with the goal of nationwide expansion.
AI Analysis
Frequently Asked Questions
- Q: What is the MySignal test?
- A: It is a non-invasive test that evaluates the risk of 10 types of cancer from stage 1 using bio-AI technology with just a urine sample.
- Q: Why is MySignal being introduced in Misocho Town?
- A: It is being introduced as the first publicly funded program by a local government to address the low cancer screening rates in rural areas with limited medical access.
- Q: Who can receive the MySignal test?
- A: Residents of Misocho Town aged 40-74 who undergo specific health check-ups in the 2026 fiscal year will be eligible, with 100 participants selected by lottery.